Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Arcus Biosciences, Inc.
Eligible patients will be randomised to 1 of 3 treatment arms: (1) zimberelimab, (2) zimberelimab + AB154 (anti-TIGIT antibody), or (3) zimberelimab + AB154 + AB928 (dual adenosine receptor antagonist). Patients that progress onzimberelimab monotherapy (treatment arm 1) may cross-over to receive combination of zimberelimab + AB154 + AB928 (in treatment arm 3).